Maria Berkman

Maria Berkman, MD, MBA, is the Head of the MedTech practice at Broadview Ventures where she manages the firm’s MedTech investment strategy and activity, from identification and screening of new opportunities through diligence, deal structure and syndication, portfolio company board management, and overarching portfolio strategy.

Maria is also the Managing Director of Longview Ventures, an independent investment vehicle focused on clinical-stage opportunities, as a complement to Broadview’s dedication to Seed and Series A financings.

Maria currently serves on the boards of Alleviant Medical, Aria CV, AtaCor, FineHeart, RapidPulse, Vascular Graft Solutions, and Vectorious Medical Technologies, and previously served on the boards of Lyra Therapeutics (NSDQ:LYRA), Apama Medical (acquired), Remedy Therapeutics (acquired), and Capricor (NSDQ:CAPR).

Prior to joining Broadview Ventures, Maria was a management consultant at Monitor Group, and trained at Mass General Brigham’s Newton Wellesley Hospital. Maria earned a concurrent MD from the UCLA School of Medicine and MBA from the Anderson School of Management at UCLA, graduating Alpha Omega Alpha.

Outside of Broadview, Maria serves as a member of the Board of Advisors at the Boston Museum of Science, member of the AdvaMed Investor Working Group, and Co-Chair of the NEVCA MedTech Academy; Maria previously served as a VC Mentor for the UCLA Biodesign Fellowship, SBIR/STTR grant reviewer for the National Science Foundation and as a Strategic Advisory Board Member for the RAD BioMed Accelerator in Tel Aviv, Israel.